197 results on '"Guidi, Sandra"'
Search Results
2. Imagine, Discover, Inspire: Proceedings of the 4th International Conference of the Trisomy 21 Research Society.
3. Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome
4. Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome
5. Cellularity Defects Are Not Ubiquitous in the Brains of Fetuses With Down Syndrome.
6. Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome
7. Neuroanatomical alterations in higher-order thalamic nuclei of fetuses with Down syndrome
8. The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome
9. Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome
10. Epigallocatechin-3-gallate
11. Contributors
12. Neurogenesis impairment: An early developmental defect in Down syndrome
13. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS
14. Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome
15. Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome
16. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome
17. Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
18. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice
19. Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome
20. Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression
21. Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period
22. Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone
23. Early Appearance of Dendritic Alterations in Neocortical Pyramidal Neurons of the Ts65Dn Model of Down Syndrome
24. Chapter 53 - Epigallocatechin-3-gallate: Linking the neurogenesis, hippocampus, and Down syndrome
25. Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model
26. Withdrawal: Nitric oxide protects neuroblastoma cells from apoptosis induced by serum deprivation through cAMP-response element-binding protein (CREB) activation
27. Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome
28. Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome
29. Widespread Proliferation Impairment and Hypocellularity in the Cerebellum of Fetuses with Down Syndrome
30. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome
31. Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders
32. Lithium Restores Neurogenesis in the Subventricular Zone of the Ts65Dn Mouse, a Model for Down Syndrome
33. Early Appearance of Dendritic Alterations in Neocortical Pyramidal Neurons of the Ts65Dn Model of Down Syndrome.
34. Neurogenesis Impairment and Increased Cell Death Reduce Total Neuron Number in the Hippocampal Region of Fetuses with Down Syndrome
35. Prenatal treatment with the flavonoid 7,8-DHF improves trisomy-linked proliferation defects in numerous brain regions of the Ts65Dn model of Down syndrome
36. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide
37. Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse
38. Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome
39. Abnormal development of the inferior temporal region in fetuses with Down syndrome
40. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome
41. Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
42. Targeting APP/AICD in Down syndrome
43. Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome.
44. Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome?
45. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome
46. Timing of therapies for Down syndrome: the sooner, the better
47. Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig
48. Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model
49. Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome
50. Is it possible to improve neurodevelopmental abnormalities in Down syndrome?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.